+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2015

1 of 4
BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary

This, ‘BioCryst Pharmaceuticals, Inc. - Product Pipeline Review - 2015’, provides an overview of the BioCryst Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioCryst Pharmaceuticals, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BioCryst Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BioCryst Pharmaceuticals, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the BioCryst Pharmaceuticals, Inc.’s pipeline products

Reasons to buy

- Evaluate BioCryst Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BioCryst Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BioCryst Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BioCryst Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioCryst Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of BioCryst Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4

Loading
LOADING...

3 of 4
List of Tables
List of Figures
BioCryst Pharmaceuticals, Inc. Snapshot
BioCryst Pharmaceuticals, Inc. Overview
Key Information
Key Facts
BioCryst Pharmaceuticals, Inc. - Research and Development Overview
Key Therapeutic Areas
BioCryst Pharmaceuticals, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
BioCryst Pharmaceuticals, Inc. - Pipeline Products Glance
BioCryst Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
BioCryst Pharmaceuticals, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
BioCryst Pharmaceuticals, Inc. - Drug Profiles
BCX-4161
Product Description
Mechanism of Action
R&D Progress
BCX-4430
Product Description
Mechanism of Action
R&D Progress
BCX-7353
Product Description
Mechanism of Action
R&D Progress
Small Molecule 2 to Inhibit Plasma Kallikrein for Hereditary Angioedema
Product Description
Mechanism of Action
R&D Progress
BCX-xxxx
Product Description
Mechanism of Action
R&D Progress
BioCryst Pharmaceuticals, Inc. - Pipeline Analysis
BioCryst Pharmaceuticals, Inc. - Pipeline Products by Target
BioCryst Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
BioCryst Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
BioCryst Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
BioCryst Pharmaceuticals, Inc. - Recent Pipeline Updates
BioCryst Pharmaceuticals, Inc. - Dormant Projects
BioCryst Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
BCX-5191
peldesine
BioCryst Pharmaceuticals, Inc. - Company Statement
BioCryst Pharmaceuticals, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
BioCryst Pharmaceuticals, Inc., Key Information
BioCryst Pharmaceuticals, Inc., Key Facts
BioCryst Pharmaceuticals, Inc. - Pipeline by Indication, 2015
BioCryst Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
BioCryst Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
BioCryst Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
BioCryst Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
BioCryst Pharmaceuticals, Inc. - Phase II, 2015
BioCryst Pharmaceuticals, Inc. - Phase I, 2015
BioCryst Pharmaceuticals, Inc. - Preclinical, 2015
BioCryst Pharmaceuticals, Inc. - Discovery, 2015
BioCryst Pharmaceuticals, Inc. - Pipeline by Target, 2015
BioCryst Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
BioCryst Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
BioCryst Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
BioCryst Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
BioCryst Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
BioCryst Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015
BioCryst Pharmaceuticals, Inc., Other Locations
BioCryst Pharmaceuticals, Inc., Subsidiaries

List of Figures
BioCryst Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
BioCryst Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
BioCryst Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
BioCryst Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
BioCryst Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
BioCryst Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
BioCryst Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll